Live Breaking News & Updates on Nasdaq listed fortress biotech

Stay informed with the latest breaking news from Nasdaq listed fortress biotech on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nasdaq listed fortress biotech and stay connected to the pulse of your community

U.S. FDA nod for Zydus Lifesciences' generic injection

U.S. FDA nod for Zydus Lifesciences' generic injection
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

Zydus-lifesciences , Sentynl-therapeutics-inc , Cyprium-therapeutics-inc , Drug-administration , Methylene-blue-injection , Provayblue-injection , Blue-injection , Methylene-blue , Nasdaq-listed-fortress-biotech , Cyprium-therapeutics ,

Zydus' US arm Sentynl buys Copper Histidinate product candidate from Cyprium

Zydus' US arm Sentynl buys Copper Histidinate product candidate from Cyprium
February 24, 2021
Sentynl acquires CUTX-101 for $20 mn in upfront and regulatory milestone payments
Zydus Cadila-owned US-based specialty pharmaceutical company Sentynl Therapeutics Inc and Cyprium Therapeutics Inc have inked a development and asset purchase agreement for latter's Copper Histidinate product candidate that is used for treatment of Menkes disease. Cyprium Therapeutics Inc is a partner company of Nasdaq-listed Fortress Biotech Inc.
As per the official statement, Sentynl has acquired CUTX-101 - Copper Histidinate - for $20 million in upfront and regulatory milestone payments through approval of the New Drug Application (NDA), as well as potential sales milestones plus royalties. The royalties on CUTX-101 net sales ranging from the mid-single digits up to the mid-twenties are also payable.

Cyprium-therapeutics-inc , Steering-committee , Drug-administration , Fortress-biotech-inc , Sentynl-therapeutics-inc , Zydus-cadila-owned , Copper-histidinate , Therapeutics-inc , Nasdaq-listed-fortress-biotech , New-drug-application , Joint-steering-committee